Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - SANGAMO THERAPEUTICS, INC | Financial_Report.xls |
| 10-K - FORM 10-K - SANGAMO THERAPEUTICS, INC | d280209d10k.htm |
| EX-31.1 - RULE 13A-14(A) CERTIFICATION OF CHIEF EXECUTIVE OFFICER - SANGAMO THERAPEUTICS, INC | d280209dex311.htm |
| EX-31.2 - RULE 13A-14(A) CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - SANGAMO THERAPEUTICS, INC | d280209dex312.htm |
| EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - SANGAMO THERAPEUTICS, INC | d280209dex321.htm |
| EX-10.57 - COLLABORATION AND LICENSE AGREEMENT - SANGAMO THERAPEUTICS, INC | d280209dex1057.htm |
| EX-10.55 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT - SANGAMO THERAPEUTICS, INC | d280209dex1055.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-174034, 333-166220, 333-157733, 333-132823, 333-64642 and 333-34196) and in the Registration Statement (Form S-3 No. 333-157732) and in the related prospectuses of Sangamo BioSciences, Inc. of our reports dated February 22, 2012, with respect to the consolidated financial statements of Sangamo BioSciences, Inc., and the effectiveness of internal control over financial reporting of Sangamo BioSciences, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2011.
/s/ Ernst & Young LLP
San Jose, California
February 22, 2012